6 completed. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
Follow Refractory Osteosarcoma: new trials by email Literature Review of Refractory Osteosarcoma trials Research Report on Refractory Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Denosumab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Completed | Children's Oncology Group | 56 | 2015-11-21 | 2024-01-22 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
Osteosarcoma (6) · Lymphoma, Non-Hodgkin (4) · Neuroblastoma (4) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Rhabdomyosarcoma (4) · Ependymoma (3) · Glioma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Medulloblastoma (3) · Rhabdoid Tumor (3) · Sarcoma (3) · Wilms Tumor (3) · Central Nervous System Neoplasms (2) · Familial ependymoma (2)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Bone Tissue (6) · Neoplasms, Connective Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Myosarcoma (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4)
CTLA-4 Antigen (1) · Denosumab (1) · Ipilimumab (1) · Nivolumab (1) · QL1206 (1) · olaparib (1) · palbociclib (1) · pepinemab (1) · tazemetostat (1)
National Cancer Institute (NCI) (4) · Children's Oncology Group (2)
United States (6) · Puerto Rico (4) · Canada (2)
Crystal L Mackall (1) · Emily G Greengard (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Rajen Mody (1) · Susan N Chi (1)
PMID 31401903, PMID 32192573, PMID 38520670, PMID 38815151, PMID 39298716
U10CA180886 (4), UM1CA097452 (2)